Evaluation of the Heat Shock Protein 90 Inhibitor Ganetespib as a Sensitizer to Hyperthermia-Based Cancer Treatments

Evaluation of the Heat Shock Protein 90 Inhibitor Ganetespib as a Sensitizer to Hyperthermia-Based Cancer Treatments

Hyperthermia is being used as a radio- and chemotherapy sensitizer for a growing range of tumor subtypes in the clinic. Its potential is limited, however, by the ability of cancer cells to activate a protective mechanism known as the heat stress response (HSR). The HSR is marked by the rapid overexp...

Full description

Bibliographic Details
Main Authors: Enzo M. Scutigliani, Yongxin Liang, Marloes IJff, Hans Rodermond, Xionge Mei, Miriam P. Korver, Vaneesha S. Orie, Ron A. Hoebe, Daisy I. Picavet, Arlene Oei, Roland Kanaar, Przemek M. Krawczyk
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
hyperthermia
heat stress response
heat shock protein 90
ganetespib
Online Access:https://www.mdpi.com/2072-6694/14/21/5250

Internet

https://www.mdpi.com/2072-6694/14/21/5250

Similar Items